# Eli Lilly Gives Hospitals Five Days to Share Claims Data or Lose 340B Discounts as IRA News Goes Quiet - Drug Pricing & IRA Round 2 - Week of June 15–22, 2026

> For the week of June 22, 2026: Eli Lilly's five-business-day 340B ultimatum letters and AbbVie's bid to rewrite the 340B patient definition dominated the tape, while the core IRA Round 2 negotiation calendar went quiet.

## Drug Pricing & IRA Round 2

### Week of June 15–22, 2026: Eli Lilly Gives Hospitals Five Days to Share Claims Data or Lose 340B Discounts as IRA News Goes Quiet

---

## TL;DR

- **The headline this week wasn't Round 2, it was 340B.** Eli Lilly is sending hospitals five-business-day ultimatum letters demanding claims data or they lose 340B pricing on Lilly drugs, and "a number of large drug makers have already adopted Lilly's policies." This is manufacturers clawing at an ~$84B discount channel in real time.
- **The IRA negotiation calendar itself went dark on the podcast tape.** Zero episodes on Round 1 MFPs, the 2028 list (Part B drugs included for the first time), the pill penalty/EPIC Act, or the Part D $2,000 cap. Quiet, not absent.
- **The structural bear case got its best evidence from a strategy insider:** a "top 25" pharma has already shifted its pipeline toward biologics for the 13-year runway "versus nine years" for small molecules. The R&D-mix shift is no longer theoretical.

## What's new

**1. Lilly weaponizes 340B data demands, and others are following.** On [Monitor Mondays (June 15)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgvxmniQ7bBU1Xe3Exs1NFhX8TJvZxGM-2BsGl1GJfc9R11G3958oDFkAeu98q1eWdctg3Uem2yVAVbjqL27AHaW8FZGh6qJX0T53tzDa1eDjhQ-3D-3DR0Hm_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUbTMSl67IbEvbNbOzIZyLsEc1Sy4bwPjXZOGaBCLbpXiiEFg4jXWqS-2F2Mxb0Ml7cTugd-2FuxJvy4xQgdtP7BQohr0jWduzlPj6P3V8O3hba1XTen3dse3VGnGMQVV-2BLfZce-2Bbk-2B1fljBJI-2BH08GS7NiXO453m-2ByJ7Y-2FCUutA8NSaw-3D-3D), Maureen Testoni, CEO of 340B Health (operator/insider, hospital-advocacy chief), laid out that Lilly "began sending ultimatum letters to selected hospitals" giving them "just five business days to begin submitting claims data to the company or risk losing 340B pricing on Lilly drugs," with "more letters" to follow. Her warning for the read-through: "a number of large drug makers have already adopted Lilly's policies and their deadlines will be upon us soon." This is the rebate-channel fight that actually moves gross-to-net.

**2. AbbVie asks a federal court to rewrite the 340B patient definition.** On [340B Unscripted (June 15)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjGNn7OAJbp945-2BULJFELiyP-2F5iNllA3mFHBmh-2FthJuqUM1e5cLKnnLcCHqLGDYMZ1JPR4SaNv8I-2FGy7PhkYcfOsxX6yDv7fVVMvdmCug8G7w-3D-3DYFv__7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUbTMSl67IbEvbNbOzIZyLsEc1Sy4bwPjXZOGaBCLbpXn4ltxLYmjU4gcRWgIgwoN03mt0-2F6xDyuNsumvKgko6yMQucrD0mXdk45T-2BPkH-2Fe98rlBR4Exc4ZeSc6S4ECftA3o6wkA5xw9Nf2eq8-2FX16lqUiCZeBIucV-2B6PsEJrdg5Q-3D-3D), healthcare attorneys walked through AbbVie's April D.C. District Court complaint seeking to impose a far narrower patient test, an "origination test," a "12-month" temporal window, and "substantive treatment-specific care," after HRSA rejected its audit work plan under the 1996 guidance. The panel (operators/insiders, practicing 340B lawyers and pharmacists) framed the stakes bluntly: this is about putting a "volume limit" on an "$84 billion" program. AbbVie is leaning on *Loper Bright* to strip HRSA's deference.

**3. MFN + IRA + Europe's JCA are converging into one margin vise.** On [Outcomes Rocket (June 16)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOi24itfKMkA8KVAk2YCqUqrVbv3bOm6rKBdIF7bB19cqOMAzRdq-2FiIRYcTklyw3cw-2BDJd8IU-2FHMxY4gGHvFC2nAV3YwdOvhkjZZJ0q4KlcXlg-3D-3DPKXQ_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUbTMSl67IbEvbNbOzIZyLsEc1Sy4bwPjXZOGaBCLbpXm-2FaMX-2FMM70N9qum9CaDznnlDzexeHazjBY-2Fypc-2BijWoUb5M0RAs1q5mfJEB7R7lXl4q-2Bk4flnDhabsFanOqDV228U3B7xgNgPGfBLgLQDnUEye8wACsRcAokFnNdFjkGA-3D-3D), Steve Mather of Lumanity (operator/insider, 40 years in pharma, ex-Sanofi commercial) called it "almost like an acceleration of climate change for the pharma industry," with "really irreversible impacts." MFN is "tying US Medicare and now Medicaid to the lowest prices abroad," forcing companies "to be much more selective about launch sequences." Why it matters for numbers: he says the IRA "fundamentally alters NPV calculations" from day one.

**4. CVS Caremark caves on Zepbound, the PBM lever has limits.** On [CareTalk (June 19)](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhPzhtNoB-2Bqlg7tjm7aUNQFEAgYPZ4bx9JkP2LsTvDMU9FByopomBdJIB8I2d4vLLTwHMmiP2T7tyLjNLHllS0gSdXsWS8yuAQXg3sFizK5mg-3D-3DwLo__7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUbTMSl67IbEvbNbOzIZyLsEc1Sy4bwPjXZOGaBCLbpXmf24OTApMEUd1cpf7rbwJhUAYjTjSq171JM8aGBzSQflrX4zUKgpUeGO0xCAHKbcrF0p-2Bu-2BbUr-2F8VzQurlUIecTZusji-2B6snOp2PZlrNoKKbGLvM6WdDHWVpmD-2FIcESxg-3D-3D), David Williams (Health Business Group) and John Driscoll (UConn Health chairman, former PBM operator) covered CVS Caremark "restoring coverage of Zepbound, reversing a formulary decision from last summer" after an ERISA class-action. Their pricing read: Lilly and Novo "were clearly charging an extortionate amount initially," visible because they "immediately were charging 70 to 80 percent less in...Europe."

**5. The Medicare GLP-1 picture firms up, barely.** Same CareTalk episode: a "Medicare-GLP-1 bridge" will "cover these drugs starting in July through the end of 2027 with Medicare footing the bill," but on Medicaid "only 13 states cover GLP-1s for obesity...down from 16 a year ago." Coverage is widening federally and narrowing at the state level at the same time.

## The debate

**The bull (manageable, modeled) view:** Every dollar of this is on the page already. IRA Round 1 MFPs hit in January, Round 2 names are knowable, and the GLP-1 "extortionate" pricing CareTalk described is exactly the cushion that lets manufacturers absorb negotiation and still clear. The 340B and MFN fights are slow-moving legal and rulemaking grinds: AbbVie's own case rests on an unsettled *Loper Bright* read, and HRSA enforcement has whipsawed for years (per 340B Unscripted, "no ineligible location test findings" from 2020–2022, then back in 2023). Litigation is not a cash-flow event this quarter.

**The bear (structural margin compression) view:** The damage is upstream of any single negotiated price. Mather's tell is the one that should worry a long book: a top-25 pharma has *already* "shift[ed] the balance more towards complex therapies to have that longer runway of 13 years versus nine years and reduce their small molecule pipeline." That's the pill penalty pulling capital out of small-molecule R&D before a single Round 2 price is set, and MFN compounds it by capping the ex-US arbitrage that funds US launches. Stack 340B erosion on top and you get permanent US gross-margin compression, not a one-time haircut.

## Stocks in play

- **LLY**: *Bull:* GLP-1 demand so strong CVS had to reverse its exclusion; pricing power intact. *Bear:* the aggressor in the 340B standoff, now legally exposed and a magnet for HRSA enforcement. *Watch:* whether the government takes the enforcement action 340B Health is demanding.
- **ABBV**: *Bull:* a win on patient definition would structurally shrink its 340B discount obligation. *Bear:* post-Humira franchise leans on small molecules (Imbruvica) most exposed to the nine-year clock. *Watch:* D.C. District Court docket on the April complaint.
- **NVO / LLY (GLP-1)**: *Bull:* Medicare bridge funds coverage July–Dec 2027. *Bear:* "70 to 80 percent" US-vs-Europe gap is the exact target of MFN. *Watch:* whether the Medicaid state count keeps falling from 13.
- **JNJ, PFE, MRK, BMY, AZN**: *No fresh podcast signal this week.* Theses unchanged; watch the 2028 selected list (first to include Part B drugs) for the next real catalyst.

## Read-throughs

- **PBMs / managed care (CVS, CI, UNH):** The Zepbound reversal shows the formulary "no" is legally fragile under ERISA, a structural ceiling on how hard PBMs can push back on blockbuster demand. Separately, an OIG review flagged that Medicare Advantage plans overturned 95% of appealed skilled-nursing denials (NaviHealth, a UnitedHealth unit, 97%), utilization-management scrutiny is rising.
- **Biosimilar / generic makers (incl. TEVA):** No fresh tape this week; the pill penalty's R&D-mix shift toward biologics is a long-run tailwind for biosimilar pipelines.
- **Small-mol vs biologic R&D mix:** Mather's "top 25" example is the cleanest data point yet that the 9-vs-13-year gap is actively reallocating pipeline dollars.
- **Ex-US launch / pricing strategy:** MFN is pushing "selective...launch sequences," expect more staggered or delayed ex-US launches to protect the US reference price.

## What changed vs last week

This is the first edition of this newsletter, so there is no prior week to diff against. Baseline established. On the core IRA Round 2 machinery, Round 1 MFPs, the 2028 list, the EPIC Act, the Part D cap, the week was genuinely quiet on the podcast tape; the action was all in the adjacent 340B and MFN fights.